1. Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
- Author
-
Freeman, Karoline, Saunders, Mark P., Uthman, Olalekan A., Taylor-Phillips, Sian, Connock, Martin, Court, Rachel, Gurung, Tara, Sutcliffe, Paul, and Clarke, Aileen
- Subjects
- *
FLUOROURACIL , *COLON cancer diagnosis , *COLON cancer patients , *COLON cancer treatment , *CHROMATOGRAPHIC analysis , *HIGH performance liquid chromatography , *THERAPEUTIC use of antimetabolites , *ANTIMETABOLITES , *ANTINEOPLASTIC agents , *COLON tumors , *PROGNOSIS , *RESEARCH funding , *TUMOR classification , *SYSTEMATIC reviews , *TREATMENT effectiveness , *KAPLAN-Meier estimator ,RECTUM tumors - Abstract
Background: Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into a desired therapeutic range may lead to fewer side effects and better patient outcomes. High performance liquid chromatography and a high throughput nanoparticle immunoassay (My5-FU) have been used in conjunction with treatment algorithms to guide dosing. The objective of this study was to assess accuracy, clinical effectiveness and safety of plasma 5-fluorouracil guided dose regimen(s) versus standard regimens based on body surface area in colorectal cancer.Methods: We undertook a systematic review. MEDLINE; MEDLINE In-Process & Other Non-Indexed Citations; EMBASE; Cochrane Library; Science Citation Index and Conference Proceedings (Web of Science); and NIHR Health Technology Assessment Programme were searched from inception to January 2014. We reviewed evidence on accuracy of My5-FU for estimating plasma 5-fluorouracil and on the clinical effectiveness of pharmacokinetic dosing compared to body surface area dosing. Estimates of individual patient data for overall survival and progression-free survival were reconstructed from published studies. Survival and adverse events data were synthesised and examined for consistency across studies.Results: My5-FU assays were found to be consistent with reference liquid chromatography tandem mass spectrometry. Comparative studies pointed to gains in overall survival and in progression-free survival with pharmacokinetic dosing, and were consistent across multiple studies.Conclusions: Although our analyses are encouraging, uncertainties remain because evidence is mainly from outmoded 5-fluorouracil regimens; a randomised controlled trial is urgently needed to investigate new dose adjustment methods in modern treatment regimens. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF